Sobi establishes MTN programme with a framework amount of SEK 10 billion, publishes a base prospectus

SEB has been appointed arranger of the MTN Programme and will also act as dealer together with Danske Bank, Nordea and Svenska Handelsbanken. Mannheimer Swartling acted as legal adviser to Sobi.

Sobi

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn.

Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

Gerard Tobin
Head of Investor Relations

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-establishes-mtn-programme-with-a-framework-amount-of-sek-10-billion--publishes-a-base-prospectu,c3967938

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/sobi-establishes-mtn-programme-with-a-framework-amount-of-sek-10-billion-publishes-a-base-prospectus-302128510.html